ROBERT JULES LEVY
Medical Practice in Merion Station, PA
License number
Pennsylvania MD062385L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Merion Station, PA 19066
Personal information
See more information about ROBERT JULES LEVY at radaris.comName
Address
Phone
4407 Willow Ave, Oakford, PA 19053
440 Merion Rd, Merion Sta, PA 19066
536 Hamilton Rd, Merion Sta, PA 19066
322 S College St, Carlisle, PA 17013
3200 Hearthstone Pl, Bensalem, PA 19020
Professional information
Derivatized Polyurethane Compositions Which Exhibit Enhanced Stability In Biological Systems And Methods Of Making The Same
US Patent:
6689861, Feb 10, 2004
Filed:
Nov 2, 2001
Appl. No.:
09/985316
Inventors:
Robert J. Levy - Merion Station PA
Ivan Alferiev - Clementon NJ
Ivan Alferiev - Clementon NJ
Assignee:
The Childrens Hospital of Philadelphi - Philadelphia PA
International Classification:
C08G 1883
US Classification:
528 72, 521 53, 525452, 525453, 525454
Abstract:
The invention relates to methods of making polyurethane derivatives which can be readily further derivatized using stabilizing agents such as anti-calcification agents, anti-thrombogenesis agents, and chemical and mechanical degradation-inhibiting agents. The invention also includes methods of making polyurethane derivatives so further derivatized and to polyurethanes derivatives made using such methods.
Magnetic Targeting Device, System And Method
US Patent:
2013026, Oct 10, 2013
Filed:
Oct 27, 2011
Appl. No.:
13/883054
Inventors:
Robert J. Levy - Merion Station PA, US
Michael Chorny - Huntingdon Valley PA, US
Ilia Fishbein - Philiadelphia PA, US
Michael Chorny - Huntingdon Valley PA, US
Ilia Fishbein - Philiadelphia PA, US
Assignee:
THE CHILDREN'S HOSPITAL OF PHILADELPHIA - Philadelphia PA
International Classification:
A61N 2/00, A61M 25/10
US Classification:
600 12
Abstract:
A treatment system includes a magnetic targeting catheter and a plurality of MNP. The MNP may include one or more magnetic field-responsive agents and one or more therapeutic agents. The catheter may include an inner shaft having at least one lumen and a fluid delivery balloon adapted to administer a fluid from the inner shaft into a space surrounding the catheter. An expandable mesh formed of a magnetizable material may surround the fluid delivery balloon. The catheter may further include one or more occlusion balloons for controlling blood flow through a vessel in which the catheter is placed. A method of treating a medical condition may include advancing a magnetic targeting catheter to a site, deploying an expandable mesh connected to the catheter, applying a magnetic field to the mesh and depositing a plurality of MNP or cells loaded with MNP near the mesh.
Sustained Release Preparations Composed Of Biocompatible Complex Microparticles
US Patent:
2007011, May 24, 2007
Filed:
Dec 9, 2004
Appl. No.:
10/582266
Inventors:
Michael Chorny - Philadelphia PA, US
Robert Levy - Merion Station PA, US
Robert Levy - Merion Station PA, US
International Classification:
A61K 39/395, A61K 38/22, A61K 38/18, A61K 31/715, A61K 9/14
US Classification:
424489000, 514012000, 514054000, 424133100
Abstract:
A particle includes a complex between a bioactive agent and a complexing agent, provided that the bioactive agent is other than a polynucleotide and an oligonucleotide, and wherein the particle has a bioactive function. The particle has a diameter from about 5 nm to about 100 microns. In certain embodiments, the bioactive agent is a member selected from the group consisting of a growth factor, a hormone, a peptide, a protein, and polysaccharide. In certain embodiments, the complexing agent is a member selected from the group consisting of polysaccharides, glycosaminoglycans, complex carbohydrates, polyacids, modifications and derivatives thereof. Also provided is a method of making the particle. Further provided is a method of administering the particle, including providing the particle, which is adapted to gradually release the bioactive agent; and thereby administering the particle.
Counteracting Bioprosthetic Calcification
US Patent:
2003019, Oct 23, 2003
Filed:
Jan 6, 2003
Appl. No.:
10/336857
Inventors:
Robert Levy - Merion Station PA, US
Ivan Alferiev - Clementon NJ, US
Ivan Alferiev - Clementon NJ, US
Assignee:
Children's Hospital of Philadelphia
International Classification:
D01C003/00
US Classification:
008/094110
Abstract:
Adapting crosslinking with triglycidyl amine (TGA) to incorporate the use of a particular type of anti-calcification agent provides a broad-reaching solution to the problem in vivo bioprosthesis calcification. The anti-calcification agent in question includes a polyphosphonate compound that contains a functional group, which serves as a reaction site between the polyphosphonate and a polyepoxide. The functional group is reactive enough to dominate the reaction between the polyphosphonate and the polyepoxide, thereby excluding the chelating oxygen atoms of polyphosphonate from the reaction, protecting their anti-calcification ability. Furthermore, the high reactivity of the functional group allows the polyphosphonate to attach to the polyepoxide more completely, which improves the calcification resistance of bioprosthetic material with which the polyepoxide is crosslinked.
Photochemical Activation Of Surfaces For Attaching Biomaterial
US Patent:
2013024, Sep 19, 2013
Filed:
Sep 7, 2012
Appl. No.:
13/606672
Inventors:
Ivan Alferiev - Clementon NJ, US
Ilia Fishbein - Jenkintown PA, US
Michael Chorny - Huntingdon Valley PA, US
Robert J. Levy - Merion Station PA, US
Benjamin Yellen - Northbrook IL, US
Darryl Williams - Philadelphia PA, US
Ilia Fishbein - Jenkintown PA, US
Michael Chorny - Huntingdon Valley PA, US
Robert J. Levy - Merion Station PA, US
Benjamin Yellen - Northbrook IL, US
Darryl Williams - Philadelphia PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
International Classification:
A61L 27/16, C08F 120/06, A61L 27/54, C08F 126/02
US Classification:
424489, 525149, 525 541, 525 542, 4352351, 5147721, 514449, 522151, 522153, 435353, 424 7818
Abstract:
A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.
Steroid Lipid-Modified Polyurethane As An Implantable Biomaterial, The Preparation And Uses Thereof
US Patent:
8193290, Jun 5, 2012
Filed:
Jun 20, 2008
Appl. No.:
12/143275
Inventors:
Robert J. Levy - Merion Station PA, US
Ivan Alferiev - Clementon NJ, US
Stanley J. Stachelek - Philadelphia PA, US
Ivan Alferiev - Clementon NJ, US
Stanley J. Stachelek - Philadelphia PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
International Classification:
C08L 89/00
US Classification:
527204, 527200, 525454, 525463, 525469, 528 65, 528 75, 528373, 568 62
Abstract:
A modified polyurethane including a lipid substituent from at least one urethane nitrogen and/or at least carbon atom of the modified polyurethane.
Uniform Field Magnetization And Targeting Of Therapeutic Formulations
US Patent:
8562505, Oct 22, 2013
Filed:
May 1, 2008
Appl. No.:
12/150864
Inventors:
Robert J. Levy - Merion Station PA, US
Boris Polyak - Philadelphia PA, US
Michael Chorny - Philadelphia PA, US
Ivan Alferiev - Clementon NJ, US
Gennady Friedman - Richboro PA, US
Darryl Williams - Philadelphia PA, US
Ilia Fishbein - Philadelphia PA, US
Boris Polyak - Philadelphia PA, US
Michael Chorny - Philadelphia PA, US
Ivan Alferiev - Clementon NJ, US
Gennady Friedman - Richboro PA, US
Darryl Williams - Philadelphia PA, US
Ilia Fishbein - Philadelphia PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
Drexel University - Philadelphia PA
Drexel University - Philadelphia PA
International Classification:
A61N 2/10
US Classification:
600 12, 600 9, 600 13, 600 15, 424422, 424426
Abstract:
Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.
Uniform Field Magnetization And Targeting Of Therapeutic Formulations
US Patent:
2010026, Oct 14, 2010
Filed:
Dec 15, 2009
Appl. No.:
12/653465
Inventors:
Robert J. Levy - Merion Station PA, US
Michael Chorny - Huntingdon Valley PA, US
Vladimir Muzykantov - Warwick PA, US
Elizabeth Hood - Philadelphia PA, US
Michael Chorny - Huntingdon Valley PA, US
Vladimir Muzykantov - Warwick PA, US
Elizabeth Hood - Philadelphia PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
The Trustees of the University of Pennsylvania - Philadelphia PA
The Trustees of the University of Pennsylvania - Philadelphia PA
International Classification:
A61K 39/44, A61N 2/10, A61F 2/82, A61M 31/00, A61K 38/44, A61P 43/00, C12N 13/00
US Classification:
4241721, 600 12, 623 142, 604500, 424 944, 4241301, 4241781, 4351735
Abstract:
Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Therapeutic particles can comprise antioxidant enzymes, and can be targeted to cells to protect the cells from oxidative damage.
Uniform Field Magnetization And Targeting Of Therapeutic Formulations
US Patent:
2013001, Jan 10, 2013
Filed:
Sep 13, 2012
Appl. No.:
13/614421
Inventors:
Robert J. Levy - Merion Station PA, US
Boris Polyak - Philadelphia PA, US
Michael Chorny - Philadelphia PA, US
Ilia Fishbein - Philadelphia PA, US
Ivan Alferiev - Clementon NJ, US
Gennady Friedman - Richboro PA, US
Darryl Williams - Philadelphia PA, US
Boris Polyak - Philadelphia PA, US
Michael Chorny - Philadelphia PA, US
Ilia Fishbein - Philadelphia PA, US
Ivan Alferiev - Clementon NJ, US
Gennady Friedman - Richboro PA, US
Darryl Williams - Philadelphia PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
International Classification:
A61K 47/12, A61K 47/34, A61K 35/76, A61K 35/12, A61K 31/337, A61K 38/43, A61K 35/00, A61K 47/42, A61K 48/00
US Classification:
424 936, 514784, 514776, 5147721, 514773, 514 44 R, 514 44 A, 514449, 424 941, 424 931, 424 937
Abstract:
Systems and methods for magnetic targeting of therapeutic particles are provided. Therapeutic particles comprise one or more magnetic or magnetizable materials and at least one therapeutic agent. Therapeutic particles are specifically targeted using uniform magnetic fields capable of magnetizing magnetizable materials, and can be targeted to particular locations in the body, or can be targeted for capture, containment, and removal. Also provided are bioresorbable nanoparticles prepared without the use of organic solvents, and methods for therapeutically using such bioresorbable nanoparticles.
Compositions And Methods For Performing Reverse Gene Therapy
US Patent:
7282489, Oct 16, 2007
Filed:
Jul 31, 2003
Appl. No.:
10/422551
Inventors:
Robert J. Levy - Merion Station PA, US
Denise Y. Burton - Bensalem PA, US
Denise Y. Burton - Bensalem PA, US
Assignee:
The Children's Hospital of Philadelphia - Philadelphia PA
International Classification:
A61K 48/00
US Classification:
514 44, 4353201, 435455
Abstract:
The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e. g. a protein) which is usually only expressed in cells of an abnormal tissue is delivered to a cell of an animal afflicted with a disease or disorder to alleviate the disease or disorder. In one embodiment, a plasmid vector encoding HERG (A561V) protein is delivered to a cell of an animal afflicted with re-entrant atrial flutter-mediated cardiac arrhythmia.